CorMedix, a specialty pharmaceutical company,
charts its business strategy around developing products for the treatment of
cardiac, renal and infectious diseases. With commercialization of these
products being its general business goal, the company specifically endeavors to
treat human disease by reducing commonly associated renal, cardiovascular,
metabolic and infectious complications. CRMD’s therapeutic candidates include
the likes of small molecules, chemical entities, biologics, devices and/or
diagnostics that enable targeted therapy in these respective areas of interest.
Market opportunity for these products abounds.
Patients meeting the challenges of hemodialysis need access to the vascular
system in order to perform treatments on different schedules each week. In an
article published by the American Journal of Kidney Diseases in February of
2008, there were 81,000 hemodialysis patients in the United States using the
central venous catheter. One of the main complications in the use of a central
venous catheter for hemodialysis treatment is CRBIs and the inflammation issues
that arise as a result. With an estimate of two cases of CRBIs per patient per
year, this would amount to over 160,000 cases each year. According the American
Journal of Kidney Diseases, the total annual cost in the United States to treat
CRBI episodes and their related complications would total approximately $777
million.
In recent news, CorMedix Inc. announced that
TUV-SUD and The Medicinal Evaluation Board of the Netherlands (MEB) granted its
request for a label expansion for its catheter lock solution, Neutrolin. The
product was originally approved in July 2013 for use in the prevention of
catheter-related bloodstream infections (CRBI) and maintenance of catheter
patency in hemodialysis patients using a tunneled, cuffed central venous
catheter for vascular access.
Approval for additional indications for use in
oncology patients receiving chemotherapy, IV hydration and IV medications via
central venous catheters is included in the label expansion. Additionally, the
expansion includes patients receiving medication and IV fluids via central
venous catheters in intensive or critical care units (cardiac care unit,
surgical care unit, neonatal critical care unit, and urgent care centers). CRMD
believes that the label expansion will enable additional critically ill
patients to benefit from the expanded use of Neutrolin thus preventing
infection and thrombosis.
CorMedix is a commercial-stage pharmaceutical
company looking to develop, license and commercialize therapeutic products for
the prevention and treatment of cardiac, renal and infectious diseases.
CorMedix’s first commercial product in Europe is Neutrolin®, a catheter lock
solution for the prevention of catheter related bloodstream infections and
maintenance of catheter patency in tunneled, cuffed, central venous catheters
used for vascular access in hemodialysis patients, in addition to oncology
patients and critical care patients. Plans are moving forward to expand
commercial distribution into the US, Asia, the Middle East, South America and
Africa following appropriate regulatory approval.
For more information on the company, visit
www.cormedix.com
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
